Skip to main content

Table 3 Cardiovascular and diabetes biochemical markers in PLWH with and without MetS

From: A cross-sectional assessment of metabolic syndrome in HIV-infected people of low socio-economic status receiving antiretroviral therapy

 

MetS (n =  29)

No MetS (n =  60)

P value

T-Chol (mg/dl)

184 ± 41

182 ± 36

0.83

LDL-C (mg/dl)

110 ± 31

107.34

0.71

HDL-C (mg/dl)

46 ± 15

53 ± 15

0.07

VLDL-C (mg/dl)

28 ± 17

22 ± 12

0.12

Non-HDL-C (mg/dl)

138 ± 35

130 ± 38

0.32

Total/HDL-C

4.2 ± 1.1

3.7 ± 1.3

0.09

TGs (mg/dl)

139 ± 84

112 ± 56

0.13

CRP (mg/L)

6.5 ± 8.3

5.3 ± 7.3

0.52

FG (mg/dl)

103 ± 51

91 ± 10

0.21

HbA1C (%; mmol/mol)*

6.4;46

5.7;39

0.03

Insulin (μU/mL)

17.3 ± 13.1

13.4 ± 7.6

0.15

Insulin resistance (HOMA)

4.3 ± 3.4

3.0 ± 1.9

0.09

  1. Data are means ± SD. *SDs for HbA1C are 1.7 (MetS) and 0.6 (No MetS).
  2. PLWH people living with HIV, MetS metabolic syndrome, T-Chol total cholesterol, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol, VLDL-C very-low density lipoprotein cholesterol, TGs triglycerides, CRP C-reactive protein, FG fasting glucose, HbA1C hemoglobin A1C, HOMA homeostasis model assessment.